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introduction
Pancreatic ductal adenocarcinoma (PDAC) represents a
signiﬁcant cause of morbidity and mortality worldwide. In the
Western world, the incidence continues to increase and it ranks
fourth as causes of cancer death [1]. About 60% of patients with
pancreatic cancer have metastatic disease at the time of
diagnosis, and of the 20% of patients who undergo a curative
resection, the majority will ultimately relapse. For all stages,
survival at 5 years is <5%, and for those with metastases the
median survival was around 6 months until recently [2]. The
metastatic setting is heterogeneous from a clinical point of view
pertaining to the number and location of metastases,
performance status and comorbidities. Moreover, PDAC has
been shown to be genetically complex: a study of xenografts and
cell lines showed that the genetic changes of resected pancreatic
cancers clustered into 12 core signalling pathways, with each
individual showing a unique proﬁle of genetic changes [3].
Excellent clinical guidelines for diagnosis and treatment of
PDAC are available [4]. However, in this rapidly evolving ﬁeld,
recent improvements in systemic chemotherapy have expanded
the therapeutic armamentarium and increased the complexity
of the decision process. This article on the management of
metastatic pancreatic cancer summarizes the expert discussion,
which was organized during the 14th European Society Medical
Oncology (ESMO)/World Congress on Gastrointestinal Cancer
(WCGIC) in June 2012 in Barcelona, Spain. Opinion leaders
and experts from different nationalities, selected on scientiﬁc
merit, participated in the discussion. In preparation for this
expert discussion, a questionnaire was sent to all participants
and the questions, answers and conclusions were rediscussed at
the meeting. The ﬁnal manuscript was reviewed by all experts in
April 2013. Expert committee reports reﬂect clinical experience
in addition to evidence-based medicine. As such, consensus was
not always reached. The main strength, however, of this
approach is that more than minimal guidelines are offered, to
assist clinicians in the process of making treatment choices in
daily clinical practice.
clinical assessment and staging of
metastatic pancreatic cancer
The assessment of patients with metastatic disease includes
history-taking, clinical examination and evaluation of
performance status. Recording the presence of comorbidities is
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important and carrying out a formal geriatric assessment is
useful. Biochemical tests include tumor markers, full blood
count, kidney and liver function tests. A contrast enhanced
computed tomography (CT)-scan of chest, abdomen and pelvis
represents the primary assessment modality for patients with
suspicion of metastatic disease. Magnetic resonance imaging is
advocated in selected cases, such as iodine contrast allergy or
characterization of ill-deﬁned/subcentimeter liver lesions, in the
context of a fatty liver or to detect small peritoneal metastases.
There is no deﬁned role for FDG-PET scintigraphy at the
moment.
In contrast to the patient population in clinical studies, the
expert panel acknowledges the different proﬁle of patients in
daily clinical practice. Many patients are older than 75 years, at
least half of them have biliary stents and are at risk for
cholangitis, 20% have co-existing heart disease and up to 30%
are not able to receive any systemic chemotherapy. The
proportion of frail patients [deﬁned as an Eastern Cooperative
Oncology Group (ECOG) performance status of ≥2] is not
exactly known.
obtaining a pathological proof
Many of the metastases are synchronous with the primary
tumour and obtaining a pathological proof is necessary to
conﬁrm the diagnosis of PDAC. There is some uncertainty
about the need for a biopsy of metastases when they are
metachronous to the primary tumour. The panel recommends a
biopsy from a metastatic lesion in case of a long (>13–14
month) interval between the resection of the primary tumour
and the appearance of a new lesion, a single lesion, absence of a
rise in CA19.9, and/or when the lesion arises in an uncommon
area. In other instances, the contribution of obtaining a biopsy
to the therapeutic decision is rather limited by the lack of
biomarkers to guide treatment selection. Nevertheless, the panel
emphasized the need for prospective collection of well-
annotated tumour material and blood from patients, preferably
within the context of clinical trials.
supportive care for patients with
metastatic pancreatic cancer
Before even considering systemic chemotherapy, patients with
metastatic pancreatic cancer may need interventions to
guarantee relief of biliary and/or duodenal obstruction,
malnutrition and pain.
In case of a biliary obstruction due to a pancreatic tumour,
the endoscopic placement of a metallic biliary stent is strongly
recommended. The endoscopic method is safer than the
percutaneous insertion and as successful as a surgical
hepatojejunostomy [5].
Duodenal obstruction is preferentially managed by
endoscopic placement of an expandable metal stent, which is
favoured over surgery [6,7].
Formal nutritional advice is mandatory in all patients and
supplementation of pancreatic enzymes may be necessary.
There are no data on the impact of additional parenteral
nutrition on survival of patients with metastatic pancreatic
cancer [8,9].
For pain not responsive to opioid analgesics or in case of poor
tolerance, a percutaneous or EUS-guided coeliac nerve block
should be considered [10]. Analgesic response rates and
duration of the analgesic effect are variable [11]. Pain and
tumour cachexia may be better controlled after starting systemic
chemotherapy, which is a typical phenomenon that has been
termed ‘clinical beneﬁt response’ in gemcitabine studies, but
even stronger positive effects on the quality of life have been
described for FOLFIRINOX [12, 13].
Patients with metastatic pancreatic cancer are at risk for
potentially lethal thromboembolic complications. A
retrospective cohort study showed that venous
thromboembolism occurs in over one-third of pancreatic cancer
patients and, whether symptomatic or incidental, is strongly
associated with worsened mortality [14]. Although the evidence
is growing that prophylactic anticoagulation with low molecular
weight heparins reduces the incidence of thrombosis in
pancreatic cancer [15], its routine general use is not yet
recommended. Further investigation is warranted, particularly
in the era of new oral non-coumarin anticoagulants.
systemic therapy for patients with
advanced pancreatic cancer: overview of
the available options
Until 2010, gemcitabine remained the sole agent with
demonstrated beneﬁt for patients with advanced pancreatic
cancer [12]. The drug was the comparator arm in many studies
(summarized in Tables 1 and 2), and the clinical value of
gemcitabine in this patient population includes a good
tolerability and safety proﬁle, a limited response rate (around
5%–10%) and 1-year overall survival (OS) of around 20% [16].
Consistently, gemcitabine arms in clinical studies demonstrated
a median survival of around 6 months. Combinations of
gemcitabine with a platinum derivative or ﬂuoropyrimidines
have only been associated with a signiﬁcant improvement in OS
in pooled and meta-analyses [17, 18].
A Canadian phase III trial showed that the addition of the
epidermal growth factor receptor tyrosine kinase inhibitor
erlotinib modestly prolonged OS when combined with
gemcitabine alone (HR, 0.81, P = 0.038) [19]. The
corresponding median and 1-year OS rates for patients who
received gemcitabine plus erlotinib versus (versus) gemcitabine
were 6.2 and 5.9 months, and 23% versus 17%, respectively.
Patients who developed a grade ≥2 skin rash had a median
survival of 10.5 months and a remarkable 1-year OS of 43%.
Despite this ﬁnding, there is no predictive marker, and it
remains unclear how to select patients for the treatment with
erlotinib. No other biologicals have so far demonstrated efﬁcacy
in phase III trials (summarized in Table 3).
A major breakthrough was reported in 2010 by a French
multicenter group who randomly assigned 342 patients with
metastatic pancreatic adenocarcinoma with a good performance
status (ECOG 0 or 1), <75 years old and nearly normal bilirubin
(≤1.5 times the upper limit of the normal range) to
FOLFIRINOX [ﬂuorouracil (400 mg/m2) given as a bolus
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followed by 2400 mg/m2 given as a 46-h continuous infusion,
leucovorin (400 mg/m2), irinotecan (180 mg/m2), oxaliplatin
(85 mg/m2) every 2 weeks) or gemcitabine (1000 mg/m2 weekly
for 7 of 8 weeks and then weekly for 3 of 4 weeks) [13]. Sixty
percent of patients had cancers of the body and tail of pancreas;
only 15.8% in the FOLFIRINOX arm and 12.9% in the GEM
arm had biliary stents. The trial was terminated early upon
recommendation of the DSMB since the primary end point was
met at an interim analysis on 192 events with 342 patients
accrued of 360 planned. The median OS was 11.1 months in the
FOLFIRINOX group compared with 6.8 months in the
gemcitabine group (HR 0.57; 95% CI, 0.45–0.73; P < 0.001). The
median progression-free survival (PFS) was 6.4 months in the
FOLFIRINOX group and 3.3 months in the gemcitabine group
(HR 0.47; 95% CI, 0.37–0.59; P < 0.001). The objective response
rate (ORR) was 31.6% in the FOLFIRINOX group versus 9.4%
in the gemcitabine group (P < 0.001). FOLFIRINOX was more
toxic than gemcitabine: 5.4% of patients in this group had
febrile neutropenia. At 6 months, 31% of the patients in the
FOLFIRINOX group had a deﬁnitive degradation of their
quality of life versus 66% in the gemcitabine group (HR, 0.47;
95% CI, 0.30–0.70; P < 0 0.001) [20]. Based on this study,
FOLFIRINOX is considered a standard treatment option for
patients with advanced pancreatic cancer with good
performance status. There are, however, major concerns about
the toxicity of the original FOLFIRINOX schedule and
therefore, modiﬁcations of FOLFIRINOX (e.g. omitting bolus 5-
FU, lower starting dose of irinotecan, dose reduction of all
agents by 20%, use of growth factors upfront) are often
implemented, although the impact of these changes on efﬁcacy
remains unclear.
More recently, results have been presented for the
nanoparticle albumin-bound form of paclitaxel (Taxol, nab-
paclitaxel) in ﬁrst-line treatment of patients with metastatic
pancreatic cancer [21]. The Metastatic Pancreatic
Adenocarcinoma Clinical Trial (MPACT) study randomly
assigned 861 metastatic pancreatic cancer patients (with normal
bilirubin values) to nab-paclitaxel (125 mg/m2) followed by
gemcitabine (1000 mg/m2) on days 1, 8 and 15 every 4 weeks, or
gemcitabine (1000 mg/m2 weekly for 7 weeks in cycle 1, then on
days 1, 8 and 15 every 4 weeks). The study showed a statistically
signiﬁcant improvement in OS compared with patients
Table 1. Combination of gemcitabine with cytotoxic chemotherapy
Author N Treatment Stage IV (%) RR (%) PFS/TTP (months) OS (months)
Roche Lima [27] 360 GEM versus
GEM+ irinotecan
82 4
16a
3
3.4
6.6
6.3
Oettle [28] 565 GEM versus
GEM+ pemetrexed
91 9
18
3.6
5.2
6.3
6.2
Abou-Alfa [29] 349 GEM versus
GEM+ exatecan
NA 6
8
3.8
3.7
6.2
6.7
Heinemann [30] 195 GEM versus
GEM+ cisplatin
73 8
10
3.1
5.3
6
7.5
Louvet [31] 313 GEM versus.
GEM+ oxaliplatin
70 17.3
26.8a
3.7
5.8a
7.1
9.0
Poplin [32] 832 GEM versus
GEM FDR versus
GEM+ oxaliplatin
88 6
10
9
2.6
3.5
2.7
4.9
6.2
5.7
Van Hoff [21] 861 GEM versus
GEM+ nab-paclitaxel
100 7
23a
3.7
5.5a
6.7
8.5a
astatistically signiﬁcant ﬁnding; GEM, gemcitabine; 5FU/FA, 5-ﬂuoruracil/folinic acid; PFS/TTP, progression-free survival/time to tumour progression; OS,
overall survival.
Table 2. Combination of gemcitabine with ﬂuoropyrimidines
Author N Treatment Stage IV (%) RR (%) PFS / TTP (months) OS (months)
Berlin [33] 327 GEM versus
GEM + bolus 5FU/FA
90 6
7
3.2
3.4
5.4
6.7
Riess [34] 466 GEM versus
GEM + 5FU/FA
77 NA 3.5
3.5
5.9
6.2
Herrmann [35] 319 GEM versus
GEM + capecitabine
80 7.8
10
3.9
4.3
7.2
8.4
Cunningham [36] 533 GEM versus
GEM + capecitabine
71 12.1
19.4
3.8
5.3a
6.2
7.1
aStatistically signiﬁcant ﬁnding; GEM, gemcitabine; 5FU/FA, 5-ﬂuorouracil/folinic acid; PFS/TTP progression-free survival/time to tumour progression; OS,
overall survival.
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receiving gemcitabine alone (median of 8.5 versus 6.7 months,
HR 0.72, P = 0.000015). The 1-year OS rate increased from 22%
to 35% (P = 0.0002). There were similar statistically signiﬁcant
beneﬁts for the combination arm in terms of PFS (5.5 versus 3.7
months, HR 0.69, P = 0.000024) and ORR (23% versus 7%,
P = 1.1 × 10−10). The most common grade ≥3 treatment-related
adverse events in the study for nab-paclitaxel and gemcitabine
versus gemcitabine alone were neutropenia (38% versus 27%),
fatigue (17% versus 7%) and neuropathy (17% versus 1%) [21].
A cross-trial comparison of the side-effects seen for
FOLFIRINOX and the nab-paclitaxel/gemcitabine combination
is given in Table 4.
In contrast to a few years ago, we have now several treatment
options for patients with metastatic pancreatic cancer. The
challenge for the clinician is how to best select one of these
options for the individual patient.
ﬁrst-line treatment of patients with
metastatic pancreatic cancer
The performance status of the patient, the serum bilirubin level,
the side-effect and tolerability proﬁle of the drug, and its
availability are currently the most important selection tools for a
given treatment. Patients should be offered participation in
clinical trials whenever possible. Given the existence of effective
therapy schedules, and taking into account their side-effects and
tolerability, the following selection is suggested by the panel:
(i) FOLFIRINOX or the nab-paclitaxel/gemcitabine
combination are reference treatments in ﬁt patients (10%–
35% of the population: ECOG 0/1, <75 years old, no or
limited comorbidities, serum bilirubin value <1.5 ULN).
The anticipated beneﬁts may be greater with FOLFIRINOX
although toxicity is considered higher for FOLFIRINOX. It
has to be mentioned that these statements have been made
based on cross-study comparisons, as direct comparative
studies have not been conducted.
(ii) Combination of gemcitabine with erlotinib, platinum
derivatives or ﬂuoropyrimidines represents options in ﬁt
patients, who are not considered candidates for
FOLFIRINOX or nab-paclitaxel (20%–30% of population).
(iii) Gemcitabine monotherapy may be reserved for patients
with poor performance status, the elderly and/or signiﬁcant
comorbidities (20%–30% of population).
Despite some promising data, there are currently no validated
predictive markers available for the most effective systemic
treatments. For gemcitabine, the presence of human
equilibrative nucleoside transporter 1 (hENT1) on tumour cells
may be a relevant predictive marker for gemcitabine. The
presence of hENT1 may allow gemcitabine to enter the tumour
cells and exert its cytotoxic effects. Interesting data have been
gathered in the adjuvant setting following resection of
pancreatic cancer [22], but there are no published validated data
for gemcitabine in the advanced setting. A phase III study with
a lipid-conjugated form of gemcitabine (CO-1.01 compound)
that can enter the cells by a hENT1 independent way failed to
show a difference in OS compared with gemcitabine (press
release Clovis Oncology, Inc.).
For nab-paclitaxel, phase I/II studies suggested that a high
expression of secreted protein acidic and rich in cysteine
(SPARC) was associated with increased median OS [23]. The
data on SPARC expression of the MPACT-trial may shed light
on the role of SPARC as a prognostic and/or predictive marker
in metastatic pancreatic cancer.
Table 4. Cross-trial comparison of grade 3/4 adverse events of
FOLFIRINOX [13] and Nab-paclitaxel/gemcitabine combination [21]
Grade 3/4 adverse
events
FOLFIRINOX (%) Nab-paclitaxel/
gemcitabine (%)
Neutropenia 46 38
Febrile neutropenia 5 3
Thrombocytopenia 9 13
Neuropathy 9 17
Fatigue 24 17
Diarrhoea 13 6
Table 3. Combination of gemcitabine with biologicals
Author N Treatment Stage IV (%) RR (%) PFS/TTP (months) OS (months)
Bramhall [37] 239 GEM versusversus
GEM+marimastat
90 11
16
3.1
2.2
5.5
5.5
Van Cutsem [38] 688 GEM versus
GEM+ zarnestra
82 16
4
3.4
3.0
6.3
6.6
Moore [19] 569 GEM versus
GEM+ erlotinib
76 9
8
3.6
3.8
5.9
6.2a
Van Cutsem [39] 607 GEM+ erlotinib versus.
GEM+ erlotinib + bevazicumab
100 8.6
13.5
3.6
4.6 a
6.0
7.1
Kindler [40] 602 GEM versus
GEM+ bevacizumab
100 13
10
2.9
3.9
5.9
5.8
Philip [41] 745 GEM versus.
GEM+ cetuximab
78 14
12
3.0
3.4
5.9
6.3
Kindler [42] 632 GEM versus
GEM+ axitinib
72 2
5
4.4
4.4
8.3
8.5
aStatistically signiﬁcant ﬁnding; GEM, gemcitabine; 5FU/FA, 5-ﬂuorouracil/folinic acid; PFS/TTP survival/time to tumour progression; OS, overall survival.
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duration and evaluation of treatment
Patients are generally treated until progression or treatment-
limiting toxicity. Treatment breaks may be offered to some
patients with limited disease burden. Treatment evaluation
should be done by a contrast-enhanced CT of chest/abdomen
and determination of serum CA19.9. The appropriate interval
between evaluations is 8 weeks, which may be shortened to 6
weeks in the early phase of treatment to identify non-
responding patients and may be prolonged to 12 weeks after
achieving disease control.
second-line treatment of patients with
metastatic pancreatic cancer
While there are established standard treatments in the ﬁrst-line
setting, there are only limited data to support a standard
second-line chemotherapy regimen. At least 30% of patients are
candidates for a second-line treatment, provided they have a
good performance status (ECOG 0/1). The choice of a regimen
depends on the performance status and the ﬁrst-line treatment.
For patients who have received prior gemcitabine-based
therapy, the only established therapy is the combination of
5-ﬂuorouracil, leucovorin and oxaliplatin (OFF), according to
the results from the phase III Charité Onkologie Clinical
(CONKO)-003 trial [24]. The study evaluated the OFF regimen
(folinic acid 200 mg/m2 followed by 5-ﬂuorouracil 2 g/m2/4 h
on d1, d8, d15, d22 and oxaliplatin 85 mg/m2 on days 8 and 22;
after a rest of 3 weeks the next cycle was started on d43) versus
best supportive care (BSC). The study was prematurely closed
because of poor accrual (inclusion of 46 patients), but the
presented results showed signiﬁcant improvements for OFF
regimen when compared with BSC, in median OS (4.8 months
versus 2.3, HR 0.45). The median OS for the sequence GEM-
OFF was 9.1 versus 7.9 months for GEM-BSC (HR 0.50,
P = 0.031) respectively.
Following FOLFIRINOX, the expert panel considers
gemcitabine to be appropriate.
A phase II study with FOLFIRINOX in 27 patients in second
line following gemcitabine showed interesting efﬁcacy, but
raised safety concerns (55% grade 3/4 neutropenia, 1 toxic
death) [25].
surgical resection or ablation of
metastases
Surgical resection or ablation of metastases is not
recommended. However, patients with a favourable tumour
biology, albeit very rare, may be offered surgery [26]. The
criteria to consider surgery include: good tumour control (>12
months) and very limited disease (single liver/lung metastasis).
conclusions and clinical research
agenda
Over the past 15 years, 1-year survival of patients with
metastatic pancreatic cancer has improved from 2% to
approaching 50% in selected patients with combination
chemotherapy. The choice for FOLFIRINOX, nab-paclitaxel/
gemcitabine or gemcitabine monotherapy is mainly driven by
age, performance status, comorbidities and therapy availability.
Candidate predictive makers (e.g. hENT1, SPARC) need to be
validated to increase the beneﬁt–risk ratio of the current
treatment regimens.
Unfortunately, many of the patients with advanced pancreatic
cancer have a poor performance status and may not tolerate the
newer more intensive cytotoxic regimens. Therefore,
modiﬁcation of the current regimens and combination with
newer targeted agents represent an unmet need. Patients should
be preferably treated within the framework of prospective
clinical studies. Those studies should contain as many
translational components as possible, as more insights will only
come from a better understanding of pancreatic tumour
biology.
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